Berlin (GTAI) – Eli Lilly and Company, one of the world’s leading producers of injectible medical products and injection devices, will be expanding its presence in Germany with a facility costing some USD 2.5 billion (EUR 2.3 billion). The company specializes in treating such conditions as diabetes, obesity and Alzheimer’s disease.
German Minister for Economic Affairs and Climate Action Robert Habeck called the project “good news for Germany," adding, “It creates new and future-oriented jobs, shows the confidence of companies in the attractiveness of Germany as a pharmaceutical and industrial location and helps to improve healthcare for our citizens.”
Construction will begin in 2024, with the production site scheduled to go operational in 2027. It will employ around 1,000 highly qualified specialists.
Germany Trade & Invest (GTAI), the country’s international business promotion agency, consulted on the project.
"This project once again proves how attractive Germany is as a business location,” says GTAI CEO Robert Hermann. “It strengthens the German pharmaceutical sector, making it more resilient in terms of supply chains. In our opinion, it doesn't get any better than a highly innovative global corporation investing in Germany and creating high-quality jobs. Both Germany and Europe will benefit from the products manufactured in Alzey."
"Every investment into our manufacturing capacity around the world is a renewed commitment to patients today – and to those who may need our medicines tomorrow,” says Edgardo Hernandez, Executive Vice President and President, Lilly Manufacturing Operations. “This state-of-the-art parenteral site with the latest technology will enable us to continue to deliver medicines with safety first and quality always around the world."